Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Peanut oral immunotherapy Clear all
Completed Phase 2 Interventional Results available

The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery

NCT02103270
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg
Drug
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy

NCT05138757
View directory record Official record
Conditions
Peanut Allergy
Interventions
Prebiotic, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Hyde Park, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Immunotherapy for Peanut and Mammalian Meat Allergies

NCT02350660
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
cow's milk, peanut powder
Dietary Supplement
Lead sponsor
University of Virginia
Other
Eligibility
4 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

Peanut Oral Immunotherapy in Children

NCT01867671
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy - Liquid Extract, Placebo for Peanut Oral Immunotherapy - Liquid Extract form, Peanut Oral Immunotherapy - Peanut Flour, Placebo for Peanut Oral Immunotherapy - Peanut Flour
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 48 Months
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Stanford, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

Oral Immunotherapy for Peanut Allergy (PMIT)

NCT00597675
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Peanut OIT, Placebo
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 3 Interventional Results available

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

NCT03292484
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
1 Year to 55 Years
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 17, 2026, 6:04 AM EDT
Active, not recruiting No phase listed Observational

Food Oral Immunotherapy for Peanut Allergy

NCT04222491
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut oral immunotherapy
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Months to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

NCT01084174
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Immediate Hypersensitivity
Interventions
Peanut powder, Peanut extract, Placebo extract, Placebo powder
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 17, 2026, 6:04 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

NCT05695261
View directory record Official record
Conditions
Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Food Allergy, Food Allergy Peanut
Interventions
Microbial Transplantation Therapy, Antibiotic, Placebo (in place of MTT), Placebo (in place of antibiotics), Oral Immunotherapy (OIT)
Biological · Drug · Other
Lead sponsor
Rima Rachid
Other
Eligibility
12 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 3 Interventional Results available

AR101 Real-World Open-Label Extension Study

NCT03337542
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Early Phase 1 Interventional

Oral Peanut Immunotherapy for Peanut Allergic Patients

NCT01891136
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut protein
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 17, 2026, 6:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

VE416 for Treatment of Food Allergy

NCT03936998
View directory record Official record
Conditions
Peanut Allergy
Interventions
Vancomycin plus VE416 before PNOIT, Vancomycin plus VE416 with PNOIT, Placebo plus VE416 with PNOIT, Placebo plus placebo with PNOIT
Combination Product
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study

NCT03345160
View directory record Official record
Conditions
Treatment Efficacy
Interventions
Peanut Flour
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
4 Years to 9 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tolerance Following Peanut Oral Immunotherapy

NCT01750879
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Flour, Oat Flour
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Not applicable Interventional

Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy

NCT01074840
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Salvage Peanut Oral Immunotherapy Study

NCT03251508
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 1 Interventional

OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

NCT04603300
View directory record Official record
Conditions
Peanut Allergy
Interventions
INT301, Placebo
Drug
Lead sponsor
Intrommune Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Belleville, New Jersey • Riverdale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

NCT02198664
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 - Peanut protein capsule
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 1 Interventional Results available

Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour)

NCT02203799
View directory record Official record
Conditions
Peanut Allergic Subjects
Interventions
Peanut Oral Immunotherapy (POIT)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
5 Years to 16 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Sep 17, 2026, 6:04 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults

NCT01274429
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 3 Interventional Results available

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)

NCT03126227
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101, Placebo
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
62
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

Mechanisms of Desensitization During Peanut Oral Immunotherapy

NCT01814241
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Open label peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 17, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

NCT03682770
View directory record Official record
Conditions
Peanut Allergy
Interventions
Dupilumab, Placebo matching dupilumab, AR101
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 17, 2026, 6:04 AM EDT